CA
NZ
UK
AU
IND
US
…
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Provectus Biopharmaceuticals is a clinical-stage company developing an intratumoral immunotherapy based on rose bengal for treatment of solid tumors. Long-term growth drivers include positive clinical data, regulatory approvals, licensing or commercialization partnerships and expansion into additional oncology indications. The therapy may benefit patients by causing local tumor ablation with potential systemic immune responses, and investors may find exposure to a differentiated, development-stage oncology asset attractive.
Primary risks are clinical or regulatory setbacks, persistent need for external financing, lack of commercial revenue and low trading liquidity of its OTCQB listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -3.55M | -5.54M | -6.68M | -7.73M | -9.00M |
| Net income | -3.55M | -5.54M | -6.68M | -6.92M | -8.15M |
| Selling general administrative | 2.02M | 2.05M | 2.15M | 2.30M | 3.31M |
| Gross profit | - | - | - | - | 0.00M |
| Reconciled depreciation | 0.01M | 0.01M | 0.24M | 0.69M | 0.69M |
| Ebit | -3.39M | -4.64M | -4.93M | -6.28M | -8.03M |
| Ebitda | -3.38M | -4.56M | -4.69M | -4.78M | -6.50M |
| Non operating income net other | - | - | 0.03M | 0.02M | 0.02M |
| Operating income | -3.39M | -4.64M | -4.96M | -6.30M | -8.05M |
| Interest expense | 0.16M | 0.96M | 1.75M | 1.46M | 0.97M |
| Interest income | - | 0.00M | 0.00M | 0.02M | 0.02M |
| Net interest income | -0.16M | -0.96M | -1.74M | -1.46M | -0.97M |
| Non recurring | - | - | - | -0.68M | -0.82M |
| Income tax expense | - | - | - | - | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 3.39M | 4.64M | 4.96M | -6.30M | 7.23M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | 0.00M | 0.06M | -0.00M | 0.70M | 0.84M |
| Net income from continuing ops | -3.55M | -5.54M | -6.68M | -7.73M | -9.00M |
| Net income applicable to common shares | -3.55M | -5.54M | -6.68M | -6.92M | -8.15M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 2.04M | 3.51M | 0.59M | 1.48M | 1.99M |
| Intangible assets | - | - | - | 0.23M | 0.90M |
| Other current assets | 1.41M | 2.42M | 0.32M | 0.35M | 0.37M |
| Total liab | 8.27M | 7.70M | 30.80M | 25.55M | 19.41M |
| Total stockholder equity | -6.23M | -4.19M | -30.21M | -24.07M | -17.42M |
| Other current liab | 1.51M | 2.65M | 2.09M | 0.08M | - |
| Common stock | 0.42M | 0.42M | 0.40M | 0.39M | 0.38M |
| Capital stock | 0.44M | 0.44M | 0.40M | 0.39M | 0.38M |
| Retained earnings | -249.59M | -246.03M | -240.49M | -233.82M | -226.89M |
| Other liab | - | - | - | 2.73M | - |
| Cash | 0.02M | 0.68M | 0.10M | 0.59M | 0.05M |
| Total current liabilities | 8.19M | 7.70M | 30.71M | 3.02M | 4.10M |
| Net debt | 2.05M | 1.02M | 23.57M | 19.58M | 13.88M |
| Short term debt | - | - | 16.62M | 0.50M | - |
| Short long term debt | 2.07M | 1.70M | 23.63M | 0.50M | - |
| Other stockholder equity | -0.04M | -0.03M | -0.03M | -0.02M | - |
| Property plant equipment | 0.14M | 0.07M | 0.04M | 0.06M | 0.07M |
| Total current assets | 1.90M | 3.44M | 0.42M | 1.00M | 1.02M |
| Net tangible assets | -6.25M | -4.21M | -30.21M | -24.30M | -18.32M |
| Net receivables | 0.00M | 0.01M | 0.00M | 0.06M | 0.60M |
| Long term debt | - | - | 0.04M | 13.00M | 13.93M |
| Accounts payable | 2.09M | 1.29M | 12.00M | 2.45M | 4.10M |
| Common stock total equity | - | - | 0.40M | 0.39M | 0.38M |
| Retained earnings total equity | - | - | -240.49M | -233.82M | -226.89M |
| Non currrent assets other | - | - | 0.12M | 0.19M | 0.97M |
| Non current assets total | 0.14M | 0.07M | 0.17M | 0.48M | 0.97M |
| Capital lease obligations | 0.12M | 0.05M | 0.13M | 0.21M | - |
| Long term debt total | - | - | - | 13.00M | 13.93M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | - | - | - | 0.00M |
| Change to liabilities | -0.18M | 2.83M | 1.82M | -0.07M | 0.65M |
| Net borrowings | 1.37M | 2.91M | 3.08M | 6.43M | 2.61M |
| Total cash from financing activities | 1.37M | 4.02M | 3.60M | 6.75M | 5.15M |
| Change to operating activities | 0.63M | 1.64M | 2.31M | 2.14M | 2.14M |
| Net income | -3.55M | -5.54M | -6.68M | -6.92M | -8.15M |
| Change in cash | -1.68M | 3.01M | -0.49M | 0.56M | -0.05M |
| Begin period cash flow | 3.11M | 0.10M | 0.59M | 0.05M | 0.11M |
| End period cash flow | 1.43M | 3.11M | 0.10M | 0.59M | 0.05M |
| Total cash from operating activities | -3.04M | -1.01M | -4.09M | -6.19M | -5.20M |
| Issuance of capital stock | 0.00M | 0.15M | - | - | - |
| Depreciation | 0.01M | 0.01M | 0.24M | 0.69M | 0.69M |
| Sale purchase of stock | - | - | 0.42M | 0.27M | 0.67M |
| Other cashflows from financing activities | - | 0.15M | 0.10M | 0.05M | 1.87M |
| Change to netincome | 0.06M | 0.04M | 0.13M | 0.02M | 0.08M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change receivables | - | - | 0.05M | 0.00M | 1.50M |
| Cash flows other operating | - | - | 0.34M | 0.09M | 0.03M |
| Cash and cash equivalents changes | - | - | -0.49M | 0.56M | -0.05M |
| Change in working capital | 0.45M | 4.47M | 2.14M | -0.05M | 2.18M |
| Stock based compensation | 0.00M | 0.02M | 0.13M | 0.02M | - |
| Other non cash items | 0.05M | 0.08M | 0.07M | 0.07M | 0.08M |
| Free cash flow | -3.04M | -1.01M | -4.09M | -6.19M | -5.20M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PVCT Provectus Biopharmaceuticals Inc |
-0.00 8.65% |
0.05 | - | - | 67.35 | 5.44 | 151.25 | -15.14 |
| NVO Novo Nordisk A/S |
0.47 1.18% |
40.78 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
10025 Investment Drive, Knoxville, TN, United States, 37932
866 594 5999
4
| Name | Title | Year Born |
|---|---|---|
| Dr. Eric A. Wachter | Co-Founder & CTO | 1963 |
| Ms. Heather Raines CPA | Chief Financial Officer | 1967 |
| Mr. Bruce Horowitz | COO & Director | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.64%
Communication Services
-0.20%
Consumer Cyclical
-0.23%
Consumer Defensive
-0.30%
Energy
+0.23%
Financial Services
-0.34%
Financials
+0.39%
Healthcare
+0.70%
Industrials
+0.42%
Real Estate
-0.37%
Technology
+1.37%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...